BiotechTube

Blinatumomab in combination with donor lymphocyte infusion

Phase 2Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation

Conditions

B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation, B-Cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Lymphoblastic Leukemia, Adult

Trial Timeline

Jun 1, 2019 → Nov 30, 2021

NCT ID
NCT03982992

About Blinatumomab in combination with donor lymphocyte infusion

Blinatumomab in combination with donor lymphocyte infusion is a phase 2 stage product being developed by Amgen for B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03982992. Target conditions include B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation, B-Cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia.

What happened to similar drugs?

20 of 20 similar drugs in B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation were approved

Approved (20) Terminated (2) Active (0)
✅PexidartinibDaiichi SankyoApproved
✅Sonidegib Phosphate CapsulesSun PharmaceuticalApproved
✅ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
✅ONTAKEisaiApproved
✅LenvatinibEisaiApproved
✅ONTAKEisaiApproved
✅MogamulizumabKyowa KirinApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03982992Phase 2Withdrawn

Competing Products

20 competing products in B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation

See all competitors
ProductCompanyStageHype Score
AFM24 + SNK01AffimedPhase 1/2
14
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
35
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
39
prednisoneKiniksa PharmaceuticalsPhase 2
29
BBP-398 with nivolumabBridgeBio PharmaPhase 1
18
Pemetrexed + CarboplatinEli LillyPhase 3
40
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
SelpercatinibEli LillyPre-clinical
26
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
40
NBTXR3NanobiotixPhase 1/2
33
Cemiplimab + CetuximabEli LillyPhase 2
42
PemetrexedEli LillyPre-clinical
26
pemetrexed + erlotinibEli LillyPhase 2
35
Necitumumab-Gemcitabine-CisplatinEli LillyPhase 2
27
LY3295668 ErbumineEli LillyPhase 1
29
CT-01 + EVEROLIMUSCaptor TherapeuticsPhase 1
26
BB-401Benitec BiopharmaPhase 2
25
FYB206 + FYB206 + KeytrudaFormycon AGPhase 3
22
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
37